Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health
Open accessThe DOI matches its Crossref record; 66 of the 94 references it cites were found in a registry or an index, and 26 are not checked yet; 13 of the 82 sources its claims cite were checked for support.
Abstract
Twenty percent of deaths in the United States are secondary to cardiovascular diseases (CVD). In patients with hyperlipidemia and hypertriglyceridemia, studies have shown high atherosclerotic CVD (ASCVD) event rates despite the use of statins. Given the association of high triglyceride (TG) levels with elevated cholesterol and low levels of high-density lipoprotein cholesterol, the American Heart Association (AHA)/American College of Cardiology (ACC) cholesterol guidelines recommend using elevated TGs as a “risk-enhancing factor” for ASCVD and using omega 3 fatty acids (Ω3FAs) for patients with persistently elevated severe hypertriglyceridemia. Ω3FA, or fish oils (FOs), have been shown to reduce very high TG levels, hospitalizations, and CVD mortality in randomized controlled trials (RCTs). We have published the largest meta-analysis to date demonstrating significant effects on several CVD outcomes, especially fatal myocardial infarctions (MIs) and total MIs. Despite the most intensive research on Ω3FAs on CVD, their benefits have been demonstrated to cluster across multiple systems and pathologies, including autoimmune diseases, infectious diseases, chronic kidney disease, central nervous system diseases, and, most recently, the COVID-19 pandemic. A review and summary of the controversies surrounding Ω3FAs, some of the latest evidence-based findings, and the current and most updated recommendations on Ω3FAs are presented in this paper.
Verified 2026-10-05 · 26 references not checked yet
Overview
CoChat Summary
TL;DR
This review summarizes evidence and controversies on omega-3 polyunsaturated fatty acids (Ω3FAs) for cardiovascular health, covering mechanisms, dietary sources, the omega-3 index, and recent randomized and meta-analytic data. It concludes that higher-dose EPA/DHA may reduce major cardiovascular outcomes, especially myocardial infarction, and recommends 2 g/d EPA/DHA generally and 4 g/d for patients with ASCVD and hypertriglyceridemia.
Key findings
- In REDUCE-IT, 8,179 statin-treated patients with fasting triglycerides 135–499 mg/dL and LDL cholesterol 41–100 mg/dL received 2 g icosapent ethyl twice daily or placebo over 4.9 years; the primary composite endpoint occurred in 17.2% vs. 22.0% (HR 0.75; 95% CI 0.68–0.83; p < 0.001), and the secondary composite of CVD death, non-fatal MI, or non-fatal stroke occurred in 11.2% vs. 14.8% (HR 0.74; 95% CI 0.65–0.83; p < 0.001).
- A meta-analysis of 13 RCTs with 127,477 participants found marine Ω3 supplementation associated with lower MI (RR 0.92; 95% CI 0.86–0.99; p = 0.020), CHD death (RR 0.92; 95% CI 0.86–0.98; p = 0.014), total CHD (RR 0.95; 95% CI 0.91–0.99; p = 0.008), CVD death (RR 0.93; 95% CI 0.88–0.99; p = 0.013), and total CVD (RR 0.97; 95% CI 0.94–0.99; p = 0.015), even when excluding REDUCE-IT.
- An earlier meta-regression of 40 interventional trials with 135,267 participants found each 1 g/day increase in Ω3 associated with a 5.8% reduction in CVD events and a 9.0% reduction in MIs; the authors’ updated meta-analysis of 42 trials with nearly 150,000 participants found each 1 g/d increase in DHA and EPA associated with a 9% reduction in MI but no reduction in CVD events.
- The omega-3 index (O3I) of 8% was associated with decreased CHD mortality risk, while an O3I below 4% increased this risk; the AHA recommends 3 ounces of cooked fish twice weekly, yet NHANES reported a 6.8% decrease in Americans older than 20 consuming seafood more than once weekly between 2005–2006 and 2015–2016.
Methods
- Narrative review/update summarizing fundamentals, controversies, and current recommendations for Ω3FAs in cardiovascular and routine clinical practice, including dietary sources, molecular mechanisms, the omega-3 index, recent data, dosage, chronic kidney disease, heart failure, brain effects, and COVID-19.
- Evidence discussed includes RCTs (e.g., DART, GISSI-Prevenzione, OMEGA, REDUCE-IT, VITAL, JELIS, STRENGTH, GISSI-HF), meta-analyses/meta-regressions (10 trials with 77,917 participants; 13 RCTs with 127,477 participants; 40 trials with 135,267 participants; updated 42 trials with nearly 150,000 participants; 21 RCTs plus 1 observational study with 2,277 participants), and observational analyses (NHANES, MESA, MERLIN-TIMI 36, CKD cohort).
- Main analysis is a narrative synthesis of selected trial and meta-analysis results; no new primary data collection or formal systematic review methods are reported.
Limitations
- The paper states that studies surrounding Ω3FAs remain controversial, individual trial results are inconsistent, and heterogeneity may arise from differences in dosages, follow-up duration, sample sizes, and lower event rates; further RCTs are necessary.
- The paper notes specific limitations of cited studies: the OMEGA trial lacked statistical power and had reduced rates of SCD, total mortality, and MACE after one year; the COVID-19 O3I pilot study was underpowered and did not reach statistical significance.
- Evident from the text: this is a narrative review rather than a systematic review or meta-analysis, with no formal search strategy, inclusion criteria, risk-of-bias assessment, or quantitative pooling reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Percentage of adults aged 20 and over consuming seafood at least two times per week, by age and sex, in the United States in 2013–2016 [23].](https://figures.cochat.ai/paper-figures/885fe8d086124bf8b454e28e194ea08f/update-on-omega-3-polyunsaturated-fatty-acids-on-cardiovascular-health-figure-2.jpg)
![Figure 3 REDUCE-IT trial prespecified endpoints. The rates of all endpoints, except death from any cause, were significantly lower in icosapent ethyl (eicosapentaenoic acid ethyl esters). Data were adapted from NEJM [5] and reproduced with Mayo Clinic Proc [57] permission.](https://figures.cochat.ai/paper-figures/f6d336123efd4d41996ebfeeffce5e76/update-on-omega-3-polyunsaturated-fatty-acids-on-cardiovascular-health-figure-3.jpg)
![Figure 4 Pooled results from a meta-analysis. Pooled estimate of relative risk and 95% confidence interval, number of studies, and the combined number of participants. CHD, coronary heart disease; CVD, cardiovascular disease; MI, myocardial infarction [52].](https://figures.cochat.ai/paper-figures/0fefd1bcdcdf4717beb84bd93d0ebe8a/update-on-omega-3-polyunsaturated-fatty-acids-on-cardiovascular-health-figure-4.jpg)
Verification
Claims the paper makes
11 Valid · 0 Not valid · 56 Not checked · 13 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Fresh seafood with high n-3 PUFAs was 32% more expensive than fresh seafood with low n-3 PUFAs (p < 0.002).”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 3. Molecular Mechanisms
What the sources say
- Supportedcites [24] Love, 2022, Affordability influences nutritional quality of seafood consumption among income and race/ethnicity groups in the United States, Am. J. Clin. Nutr. source
The Results section, “Retail price and intake of seafood high in n–3 PUFAs,” states that fresh seafood high in n–3 PUFAs was 32% more expensive than fresh seafood low in n–3 PUFAs, with P < 0.002. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A diet low in Ω3FAs is associated with increased mortality and CHD risk [5,38,51,52]”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 5. Index
What the sources say
- Not checked yetcites [5] Bhatt, 2019, Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia, N. Engl. J. Med. source
- Could not verifycites [38] Bhatt, 2020, REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States, Circulation sourceExperimental — accuracy not yet measured
The Methods describe a trial of icosapent ethyl versus placebo in statin-treated patients with elevated triglycerides, and the Discussion reports cardiovascular and mortality outcomes for those groups (page numbers unavailable). Searches for low dietary omega-3 intake and its association with mortality or CHD risk found no passage addressing that relationship. (LLM, conf=0.77)
- Partly supportedcites [51] Hu, 2019, Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127,477 Participants, J. Am. Heart Assoc. sourceExperimental — accuracy not yet measured
The Results report lower total CHD and CHD-death risk with marine omega-3 supplementation, and the Introduction notes an association between higher fish consumption and lower heart-disease risk. But the paper does not establish that a diet low in omega-3 fatty acids is associated with increased mortality overall; its mortality findings concern CHD and CVD deaths in supplementation trials. No page numbers are provided in our copy. (LLM, conf=0.86)
- Partly supportedcites [52] Bernasconi, 2021, Omega-3 Benefits Remain Strong Post-STRENGTH, Mayo Clin. Proc. sourceExperimental — accuracy not yet measured
In “Omega-3 Benefits Remain Strong Post-STRENGTH” (page not provided), the authors report lower CHD event risk and CHD mortality with EPA and DHA intake. That supports the direction of the CHD-risk claim, but the paper does not establish that a diet low in omega-3s increases overall mortality; its mortality findings are specific to CHD and fatal myocardial infarction. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“According to the study, Ω3FA supplements did not prevent fatal MIs and strokes in people with a high CVD risk [56].”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 6. Recent Data
What the sources say
- Supportedcites [56] Aung, 2018, Associations of Omega-3 Fatty Acid Supplement Use with Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77917 Individuals, JAMA Cardiol. source
The Discussion (p. Abstract/Discussion, passage 2) states that randomization to omega-3 FA supplementation over a mean of 4.4 years 'had no significant effect on either of fatal CHD, nonfatal MI, stroke, revascularization events, or any major vascular events,' and the Abstract Findings echo this for fatal coronary heart disease. The Abstract 'Meaning' section explicitly frames the population as 'people who have or at high risk of developing cardiovascular disease,' matching the citing sentence's high-CVD-risk qualifier. Interpreting 'fatal MIs' as the paper's fatal CHD endpoint is a faithful paraphrase. (LLM, conf=0.90)
plainn = 77,917- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“EPA's ability to stabilize cell membranes, along with its ability to lower cholesterol, may contribute to the 30% and 40% reductions seen in deaths from CVD and sudden cardiac death (SCD) and the 56% reduction in cardiac arrest [31].”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 3. Molecular Mechanisms
What the sources say
- Partly supportedcites [31] Gaba, 2022, Prevention of Cardiovascular Events and Mortality with Icosapent Ethyl in Patients with Prior Myocardial Infarction, J. Am. Coll. Cardiol. sourceExperimental — accuracy not yet measured
The Results (Study Population and Baseline Characteristics; page unavailable) report 30%, 40%, and 56% relative risk reductions in cardiovascular death, sudden cardiac death, and cardiac arrest, respectively, with icosapent ethyl among patients with prior myocardial infarction. The paper describes EPA-related membrane stabilization, but does not identify cholesterol lowering as an EPA mechanism contributing to these outcomes; it says the mechanistic basis remains unclear. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Based on a meta-analysis and meta-regression of 40 interventional trials involving 135,267 participants, Ω3 proved to have dose-dependent significant protective effects against CVD and MI [57].”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 7. Importance of Dosage
What the sources say
- Supportedcites [57] Bernasconi, 2021, Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis and Meta-Regression of Interventional Trials, Mayo Clin. Proc. source
The Characteristics of Included Studies section reports 40 trials with participant counts totaling 135,267. The Meta-Regression section reports statistically significant dose-dependent reductions in CVD events and MI with higher EPA and DHA dosages. (LLM, conf=0.92)
plainstates a causen = 135,267- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
35 more claims · 3 with their cited sources checked
Create a free account to see all 80 claims and to verify the 69 references still open.
- It may state two separate claims as one. 37
- Probably not a substantial claim. 3
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, a meta-analysis of 90 RCTs (n = 72,598) demonstrated a dose-response relationship between omega-3 intake and reductions in triglycerides and non-HDL cholesterol, particularly in hyperlipidemia, overweight/obesity, or coronary heart disease, and more evident with doses >2 g/day or in those on lipid-lowering therapy [299].”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [299]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 9. Heart Failure (HF)
“Hence the 2022 AHA/ACC guidelines for managing HF have outlined that Ω3FAs might be reasonably used as an adjunctive therapy on patients with HF class II-IV symptoms to reduce mortality and CVD hospitalizations [68].”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > References
“68. Mehra, M.R.; Lavie, C.J.; Ventura, H.O.; Milani, R.V. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J. Heart Lung Transplant. 2006, 25, 834-838. [CrossRef]”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 8. Chronic Kidney Disease (CKD)
“second (0.87-1.30g/day)”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 8. Chronic Kidney Disease (CKD)
“third (0.87-1.30g/day)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 2. Dietary Sources and Guidelines
“finding an inverse correlation of the O3I with CHD.”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 5. Index
“Its levels were demonstrated to have a direct correlation with the risk of death from CHD, where an O3I value of 8% decreased the risk of CHD mortality and a percentage less than 4% increased this risk [55].”
Citations
Cites
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Health inequalities among British civil servants: the Whitehall II study
Marmot, M. G., Stansfeld, S., Patel, C., North, F., Head, J., White, I., Brunner, E., Feeney, A., Marmot, M. G., & Smith, G. D. (1991) · The Lancet · doi:10.1016/0140-6736(91)93068-k · Cited by 3,608
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · cited 9×
“, in the REDUCE-IT trial [5], used four times the dose of Ω3FAs (IPE 2 g twice daily) used in the VITAL trial.”
BackgroundMethodInfluentialBurr, M. L., Gilbert, J. F., Holliday, R. M., Elwood, P. C., Fehily, A. M., Rogers, S., Sweetnam, P. M., & Deadman, N. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90828-3 · Cited by 2,610 · cited 1×
“The Diet and Reinfarction Trial (DART) [35] was the first RCT to show a reduction in mortality during the two years after myocardial infarction (MI) among men who were advised to eat about 300 g of FO per week or who took an equivalent amount of n-3 fatty acids in the form of FO supplements.”
BackgroundYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516 · cited 1×
“The Effects of EPA on Major CHD Events in Hypercholesterolemic Patients (JELIS) trial was a randomized, open-label, blinded endpoint analysis conducted in Japan between 1996 and 1999 [50].”
BackgroundTriglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419 · cited 1×
“Furthermore, as elevated triglycerides (TGs) appear to be a causal factor for atherosclerotic CVD (ASCVD) and possibly for premature all-cause mortality, more so when they are associated with genetic variants, PUFAs can reduce TG levels by decreasing lipoproteins with high amounts of TGs, such as very-low-density lipo…”
BackgroundGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators
Serhan, C. N., & Levy, B. D. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97943 · Cited by 1,344 · cited 2×
“, obesity), diabetes, and autoimmune diseases [88].”
BackgroundImportance of n−3 fatty acids in health and disease
Connor, W. E. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.1.171s · Cited by 1,344
Marchioli, R., Barzi, F., Bomba, E., Chieffo, C., Di Gregorio, D., Di Mascio, R., Franzosi, M. G., Geraci, E., Levantesi, G., Maggioni, A. P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000014682.14181.f2 · Cited by 1,311
The Omega-3 Index: A new risk factor for death from coronary heart disease?
Harris, W. S., & von Schacky, C. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2004.02.030 · Cited by 1,111 · cited 3×
“Its levels were demonstrated to have a direct correlation with the risk of death from CHD, where an O3I value of 8% decreased the risk of CHD mortality and a percentage less than 4% increased this risk [55].”
BackgroundInfluentialMfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid
Nguyen, L. N., Ma, D., Shui, G., Wong, P., Cazenave-Gassiot, A., Zhang, X., Wenk, M. R., Goh, E. L. K., & Silver, D. L. (2014) · Nature · doi:10.1038/nature13241 · Cited by 1,048 · cited 1×
“Conversion of plant-derived ALA to DHA is minimal in humans; moreover, these fatty acids cannot be synthesized de novo in the brain or retina, and their absorption depends on proteins such as Major Facilitator Superfamily Domain Containing 2A (MFSD2A), which absorbs them in the form of lysophosphatidylcholine [74,75].”
BackgroundHEALTH BENEFITS OF DOCOSAHEXAENOIC ACID (DHA)
HORROCKS, L. A., & YEO, Y. K. (1999) · Pharmacological Research · doi:10.1006/phrs.1999.0495 · Cited by 1,031
Nicholls, S. J., Lincoff, A. M., Garcia, M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., et al. (2020) · JAMA · doi:10.1001/jama.2020.22258 · Cited by 1,028 · cited 1×
“However, since this meta-analysis, two major trials have been published with negative results [47,48].”
BackgroundMarine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Albert, C. M., Gordon, D., Copeland, T., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811403 · Cited by 979 · cited 1×
“However, this trial showed that just 840 mg of combined EPA/DHA significantly reduced MI and major CHD events [63].”
BackgroundMechanisms of action of docosahexaenoic acid in the nervous system
Salem, N., Litman, B., Kim, H., & Gawrisch, K. (2001) · Lipids · doi:10.1007/s11745-001-0805-6 · Cited by 919
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885 · cited 1×
“Furthermore, as elevated triglycerides (TGs) appear to be a causal factor for atherosclerotic CVD (ASCVD) and possibly for premature all-cause mortality, more so when they are associated with genetic variants, PUFAs can reduce TG levels by decreasing lipoproteins with high amounts of TGs, such as very-low-density lipo…”
BackgroundDocosahexaenoic acid: Membrane properties of a unique fatty acid
Stillwell, W., & Wassall, S. R. (2003) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(03)00101-4 · Cited by 872 · cited 1×
“Once absorbed, Ω3FAs become part of the cell membranes and have the ability to affect several of their properties, including modulating the activity of membrane-bound enzymes and cell signaling pathways [53,54].”
BackgroundThies, F., Garry, J. M., Yaqoob, P., Rerkasem, K., Williams, J., Shearman, C. P., Gallagher, P. J., Calder, P. C., & Grimble, R. F. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12468-3 · Cited by 739
Is a “Cytokine Storm” Relevant to COVID-19?
Sinha, P., Matthay, M. A., & Calfee, C. S. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.3313 · Cited by 717
PLASMA LIPID AND LIPOPROTEIN PATTERN IN GREENLANDIC WEST-COAST ESKIMOS
Bang, H. O., Dyerberg, J., & Nielsen, A. B. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91658-8 · Cited by 690 · cited 1×
“[2], the first to show a connection between fish oil (FO) and CV health, CVD continues to be the number one cause of death in the US and the world [3].”
BackgroundMortality in the United States
(1840) · The Boston Medical and Surgical Journal · doi:10.1056/nejm184002260220306 · Cited by 648
Omega-3 polyunsaturated fatty acids and cardiovascular diseases.
Lavie, C. J., Milani, R. V., Mehra, M. R., & Ventura, H. O. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.084 · Cited by 644
Self-citationAndreone, B. J., Chow, B. W., Tata, A., Lacoste, B., Ben-Zvi, A., Bullock, K., Deik, A. A., Ginty, D. D., Clish, C. B., & Gu, C. (2017) · Neuron · doi:10.1016/j.neuron.2017.03.043 · Cited by 636
Aung, T., Halsey, J., Kromhout, D., Gerstein, H. C., Marchioli, R., Tavazzi, L., Geleijnse, J. M., Rauch, B., Ness, A., Galan, P., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.5205 · Cited by 632 · cited 2×
“Accordi g to the study, Ω3FA supplements did ot prevent fatal MIs and strokes in peo‐ ple with a high CVD risk [56].”
Siscovick, D. S., Barringer, T. A., Fretts, A. M., Wu, J. H. Y., Lichtenstein, A. H., Costello, R. B., Kris-Etherton, P. M., Jacobson, T. A., Engler, M. B., Alger, H. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000482 · Cited by 629
Nemets, B., Stahl, Z., & Belmaker, R. H. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.477 · Cited by 627 · cited 2×
“Furthermore, when Ω3FA is given as add-on therapy, double-blind, placebo-controlled trials have found an added therapeutic benefit, demonstrated by improvements in the Positive and Negative Syndrome Scale (PANSS) [83,85,86].”
Mortality in the United States, 2020
(2021) · doi:10.15620/cdc:112079 · Cited by 526 · cited 1×
“[2], the first to show a connection between fish oil (FO) and CV health, CVD continues to be the number one cause of death in the US and the world [3].”
BackgroundRimm, E. B., Appel, L. J., Chiuve, S. E., Djoussé, L., Engler, M. B., Kris-Etherton, P. M., Mozaffarian, D., Siscovick, D. S., Lichtenstein, A. H., & On behalf of the American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology (2018) · Circulation · doi:10.1161/cir.0000000000000574 · Cited by 500
Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis
Khan, S. U., Lone, A. N., Khan, M. S., Virani, S. S., Blumenthal, R. S., Nasir, K., Miller, M., Michos, E. D., Ballantyne, C. M., Boden, W. E., et al. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.100997 · Cited by 411
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
Mason, R. P., Libby, P., & Bhatt, D. L. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313286 · Cited by 407 · cited 2×
“It is imperative to note that brain function is determined not only by the brain’s structure but also by the perfusion of the brain, which is modulated by vasoactive derivatives of Ω3FAs [34].”
BackgroundSocioeconomic inequalities in cardiovascular disease mortality. An international study
Mackenbach, J. (2000) · European Heart Journal · doi:10.1053/euhj.1999.1990 · Cited by 404
Kris-Etherton, P., Eckel, R. H., Howard, B. V., St. Jeor, S., & Bazzarre, T. L. (2001) · Circulation · doi:10.1161/01.cir.103.13.1823 · Cited by 402
Why do omega-3 fatty acids lower serum triglycerides?
Harris, W. S., & Bulchandani, D. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000236363.63840.16 · Cited by 398 · cited 1×
“Ω3FAs such as EPA and DHA reduce TG levels by direct inhibiting liver diacylglycerol acetyl-transferase, which catalyzes the formation of TG from diacylglycerol, essential for TG intestinal absorption and fatty acyl-CoA, and the inhibition of the phosphatidic acid phosphohydrolase required for triacylglycerol (TAG) sy…”
BackgroundHu, Y., Hu, F. B., & Manson, J. E. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013543 · Cited by 388 · cited 3×
“A diet low in Ω3FAs is associated with increased mortality and CHD risk [5,38,51,52], although, as concentrations of Ω3 vary among varieties of food and among types of fish and vegetables, measuring the amount of Ω3 consumed by a person is not a reliable indicator of the level of Ω3 in the organism.”
BackgroundResultSocioeconomic Status and Stroke: An Updated Review
Addo, J., Ayerbe, L., Mohan, K. M., Crichton, S., Sheldenkar, A., Chen, R., Wolfe, C. D. A., & McKevitt, C. (2012) · Stroke · doi:10.1161/strokeaha.111.639732 · Cited by 373
n -3 Fatty acids, inflammation and immunity: new mechanisms to explain old actions
Calder, P. C. (2013) · Proceedings of the Nutrition Society · doi:10.1017/s0029665113001031 · Cited by 364 · cited 1×
“Once absorbed, Ω3FAs become part of the cell membranes and have the ability to affect several of their properties, including modulating the activity of membrane-bound enzymes and cell signaling pathways [53,54].”
BackgroundThe lipid composition of adult rat brain synaptosomal plasma membranes
BRECKENRIDGE, W. (1972) · Biochimica et Biophysica Acta · doi:10.1016/0006-3002(72)90012-1 · Cited by 349
Bioavailability of long-chain omega-3 fatty acids
Schuchardt, J. P., & Hahn, A. (2013) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2013.03.010 · Cited by 344
The lipid composition of adult rat brain synaptosomal plasma membranes
Breckenridge, W. C., Gombos, G., & Morgan, I. G. (1972) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(72)90365-3 · Cited by 340
Peet, M., Brind, J., Ramchand, C. N., Shah, S., & Vankar, G. K. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00083-9 · Cited by 329 · cited 2×
“Furthermore, when Ω3FA is given as add-on therapy, double-blind, placebo-controlled trials have found an added therapeutic benefit, demonstrated by improvements in the Positive and Negative Syndrome Scale (PANSS) [83,85,86].”
Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction
Kalstad, A. A., Myhre, P. L., Laake, K., Tveit, S. H., Schmidt, E. B., Smith, P., Nilsen, D. W. T., Tveit, A., Fagerland, M. W., Solheim, S., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052209 · Cited by 311 · cited 1×
“However, since this meta-analysis, two major trials have been published with negative results [47,48].”
BackgroundTargeting inflammation in metabolic syndrome
Welty, F. K., Alfaddagh, A., & Elajami, T. K. (2016) · Translational Research · doi:10.1016/j.trsl.2015.06.017 · Cited by 287 · cited 1×
“Additionally, Ω3FAs’ are precursors to the synthesis of specialized mediators capable of combating inflammation and have been demonstrated to decrease proinflammatory cytokines such as interleukine-6 and tumor necrosis factor-α and inhibit the activation of the ikappaB kinase and nuclear factor-κB, as well as several…”
BackgroundWei, M. Y., & Jacobson, T. A. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0210-3 · Cited by 284
Jacobson, T. A., Glickstein, S. B., Rowe, J. D., & Soni, P. N. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.10.018 · Cited by 263
Effect of Omega-3 Dosage on Cardiovascular Outcomes
Bernasconi, A. A., Wiest, M. M., Lavie, C. J., Milani, R. V., & Laukkanen, J. A. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.08.034 · Cited by 237 · cited 4×
“Based on a meta-analysis and meta-regression of 40 interventional trials involving 135,267 participants, Ω3 proved to have dose-dependent significant protective effects against CVD and MI [57].”
MethodInfluentialSelf-citationGuemez-Gamboa, A., Nguyen, L. N., Yang, H., Zaki, M. S., Kara, M., Ben-Omran, T., Akizu, N., Rosti, R. O., Rosti, B., Scott, E., et al. (2015) · Nature Genetics · doi:10.1038/ng.3311 · Cited by 225 · cited 1×
“In addition, this mutation has been linked to diseases such as autosomal recessive primary microcephaly-15 [76,77].”
BackgroundOmega-3 fatty acids and cancers: a systematic update review of epidemiological studies
Gerber, M. (2012) · British Journal of Nutrition · doi:10.1017/s0007114512001614 · Cited by 214
Gioxari, A., Kaliora, A. C., Marantidou, F., & Panagiotakos, D. P. (2018) · Nutrition · doi:10.1016/j.nut.2017.06.023 · Cited by 203
Erkkilä, A. T., Lehto, S., Pyörälä, K., & Uusitupa, M. I. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/78.1.65 · Cited by 200
Effects of education and income on cardiovascular outcomes: A systematic review and meta-analysis
Khaing, W., Vallibhakara, S. A., Attia, J., McEvoy, M., & Thakkinstian, A. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317705916 · Cited by 189
Importance of EPA and DHA Blood Levels in Brain Structure and Function
von Schacky, C. (2021) · Nutrients · doi:10.3390/nu13041074 · Cited by 174 · cited 1×
“On the other hand, a lower O3I value is associated with reduced brain volume, impaired cognition, accelerated progression to dementia, and increased risk of ischemic CVA and death [81].”
BackgroundSocioeconomic position and incidence of acute myocardial infarction: a meta-analysis
Manrique-Garcia, E., Sidorchuk, A., Hallqvist, J., & Moradi, T. (2010) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2009.104075 · Cited by 170
Omega-3 fatty acids' supplementation in Alzheimer's disease: A systematic review
Canhada, S., Castro, K., Perry, I. S., & Luft, V. C. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1321813 · Cited by 156
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
Bhatt, D. L., Miller, M., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044440 · Cited by 136
Albert, C. M., Cook, N. R., Pester, J., Moorthy, M. V., Ridge, C., Danik, J. S., Gencer, B., Siddiqi, H. K., Ng, C., Gibson, H., et al. (2021) · JAMA · doi:10.1001/jama.2021.1489 · Cited by 133
De Caterina, R., & Massaro, M. (2005) · Journal of Membrane Biology · doi:10.1007/s00232-005-0783-2 · Cited by 130
Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure
Mehra, M. R., Lavie, C. J., Ventura, H. O., & Milani, R. V. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2006.03.005 · Cited by 122 · cited 1×
“We hypothesized many years ago that higher doses of Ω3 may be particularly beneficial for advanced HF and cardiac cachexia, and RCTs are still needed in these HF patients [69].”
BackgroundSelf-citationBlood omega-3 fatty acids and death from COVID-19: A pilot study
Asher, A., Tintle, N. L., Myers, M., Lockshon, L., Bacareza, H., & Harris, W. S. (2021) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2021.102250 · Cited by 118 · cited 7×
“However, as indicated by the trend, more well-powered studies are needed to demonstrate the benefit of Ω3 in COVID-19 [91].”
MethodInfluentialHusson, M.-O., Ley, D., Portal, C., Aumar, M., Hueso, T., Desseyn, J., & Gottrand, F. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.10.001 · Cited by 111
The lysolipid transporter Mfsd2a regulates lipogenesis in the developing brain
Chan, J. P., Wong, B. H., Chin, C. F., Galam, D. L. A., Foo, J. C., Wong, L. C., Ghosh, S., Wenk, M. R., Cazenave-Gassiot, A., & Silver, D. L. (2018) · PLOS Biology · doi:10.1371/journal.pbio.2006443 · Cited by 107 · cited 1×
“In addition, this mutation has been linked to diseases such as autosomal recessive primary microcephaly-15 [76,77].”
BackgroundPeet, M. (2003) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2003.08.020 · Cited by 103 · cited 3×
“In patients with major depressive disorder and those with schizophrenia [83], low consumption of Ω3FAs has been identified [84].”
BackgroundPredicting the effects of supplemental EPA and DHA on the omega-3 index
Walker, R. E., Jackson, K. H., Tintle, N. L., Shearer, G. C., Bernasconi, A., Masson, S., Latini, R., Heydari, B., Kwong, R. Y., Flock, M., et al. (2019) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqz161 · Cited by 93 · cited 1×
“This was later demonstrated by an inverse correlation between the O3I and disease activity [90].”
BackgroundHoly, E. W., Forestier, M., Richter, E. K., Akhmedov, A., Leiber, F., Camici, G. G., Mocharla, P., Lüscher, T. F., Beer, J. H., & Tanner, F. C. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.226118 · Cited by 88
Relationship Between Fish Consumption and Disease Activity in Rheumatoid Arthritis
Tedeschi, S. K., Bathon, J. M., Giles, J. T., Lin, T., Yoshida, K., & Solomon, D. H. (2017) · Arthritis Care & Research · doi:10.1002/acr.23295 · Cited by 85 · cited 1×
“recombinant bivalent fusion protein (RvEs), protectin D1 or neuroprotectin D1 (PD1), protectin DX (PDX), and the pro-resolving lipid mediator maresin 1 (MaR1), which reduce circulating inflammatory cytokines, thereby reducing inflammatory-mediated diseases such as rheumatoid arthritis (RA) disease activity [88,89].”
BackgroundOverview of Prescription Omega-3 Fatty Acid Products for Hypertriglyceridemia
WEINTRAUB, H. S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2828 · Cited by 82
n-3 Polyunsaturated Fatty Acids: Promising Nutrients for Preventing Cardiovascular Disease
Yagi, S., Fukuda, D., Aihara, K., Akaike, M., Shimabukuro, M., & Sata, M. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17013 · Cited by 81
Fialkow, J. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0170-7 · Cited by 80
Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids
Weinberg, R. L., Brook, R. D., Rubenfire, M., & Eagle, K. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.060 · Cited by 63 · cited 1×
“High consumption of polyunsaturated fatty acids (PU FAs), specifically omega-3 FAs (Ω3FAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), results in low plasma cholesterol levels and minimal coronary heart disease (CHD) [4,5].”
BackgroundGaba, P., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.035 · Cited by 61 · cited 2×
“EPA’s ability to stabilize cell membranes, along with its ability to lower cholesterol, may contribute to the 30% and 40% reductions seen in deaths from CVD and sudden cardiac death (SCD) and the 56% reduction in cardiac arrest [31].”
BackgroundLove, D. C., Thorne-Lyman, A. L., Conrad, Z., Gephart, J. A., Asche, F., Godo-Solo, D., McDowell, A., Nussbaumer, E. M., & Bloem, M. W. (2022) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac099 · Cited by 56 · cited 1×
“[24], finding that individuals with lower incomes consumed less seafood (120.”
Jialal, I., Devaraj, S., Huet, B., & Traber, M. G. (1999) · The Lancet · doi:10.1016/s0140-6736(99)90191-5 · Cited by 53
Effect of omega‐3 fatty acids on disease severity in patients with psoriasis: A systematic review
Upala, S., Yong, W. C., Theparee, T., & Sanguankeo, A. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13051 · Cited by 49
Depletion of docosahexaenoic acid in red blood cell membranes of depressive patients
Edwards, R., Peet, M., Shay, J., & Horrobin, D. (1998) · Biochemical Society Transactions · doi:10.1042/bst026s142 · Cited by 44 · cited 1×
“In patients with major depressive disorder and those with schizophrenia [83], low consumption of Ω3FAs has been identified [84].”
BackgroundOmega-3 Benefits Remain Strong Post-STRENGTH
Bernasconi, A. A., Lavie, C. J., Milani, R. V., & Laukkanen, J. A. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.03.004 · Cited by 37 · cited 6×
“CHD, coronary heart disease; CVD, cardiovascular disease; MI, myocardial infarction [52].”
BackgroundInfluentialSelf-citationPertiwi, K., Küpers, L. K., de Goede, J., Zock, P. L., Kromhout, D., & Geleijnse, J. M. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022617 · Cited by 32
Selvaraj, S., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Juliano, R. A., Jiao, L., Tardif, J., Ballantyne, C. M., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024999 · Cited by 31 · cited 2×
“analyzed patients in the REDUCE-IT trial and, by implementing the Cox regression model, estimated the risk of outcomes of participants with and without HF [65].”
MethodSingh, S., Arora, R. R., Singh, M., & Khosla, S. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000165 · Cited by 28
Controversies in omega-3 efficacy and novel concepts for application
Radcliffe, J., Thomas, J., Bramley, A. L., Kouris‐Blazos, A., Radford, B. E., Scholey, A. B., Pipingas, A., Thomas, C., & Itsiopoulos, C. (2016) · Journal of Nutrition & Intermediary Metabolism · doi:10.1016/j.jnim.2016.05.002 · Cited by 28 · cited 1×
“Moreover, as DHA constitutes an essential component of neuronal membranes, changes to these membranes produce modifications to the proteins and receptors embedded within the membrane, hence altering neuronal activity [82].”
BackgroundSea Change for Marine Omega-3s
O'Keefe, E. L., Harris, W. S., DiNicolantonio, J. J., Elagizi, A., Milani, R. V., Lavie, C. J., & O'Keefe, J. H. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.04.027 · Cited by 28
Self-citationRamadeen, A., Connelly, K. A., Leong-Poi, H., Hu, X., Fujii, H., Laurent, G., Domenichiello, A. F., Bazinet, R. P., & Dorian, P. (2012) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.112.971515 · Cited by 27 · cited 1×
“Initial studies in animal labs demonstrated that supplementation with DHA, but not EPA, reduced arrhythmogenic structural changes to the atria resulting from simultaneous atrial and ventricular pacing [45].”
BackgroundZelniker, T. A., Morrow, D. A., Scirica, B. M., Furtado, J. D., Guo, J., Mozaffarian, D., Sabatine, M. S., & O’Donoghue, M. L. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.017401 · Cited by 26 · cited 1×
“25), independent of traditional CVD risk factors and lipids [59].”
BackgroundSeafood Consumption in the United States, 2013-2016.
Terry, A. L., Herrick, K., Afful, J., & Ahluwalia, N. (2018) · PubMed · Cited by 23
Kapoor, K., Alfaddagh, A., Rifai, M. A., Bhatt, D. L., Budoff, M. J., Nasir, K., Miller, M. J., Welty, F. K., McEvoy, J. W., Dardari, Z., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021431 · Cited by 22 · cited 1×
“These findings were later contradicted by The MESA study (Multiethnic Study of Atherosclerosis), which examined the relationship between Ω3FAs (expressed as a percentage mass of total fatty acids) and the risk of major bleeding events and AF [49].”
ResultGao, Z., Zhang, D., Yan, X., Shi, H., & Xian, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.904250 · Cited by 22
Dietary α-linolenic acid increases the platelet count in ApoE−/− mice by reducing clearance
Stivala, S., Reiner, M. F., Lohmann, C., Lüscher, T. F., Matter, C. M., & Beer, J. H. (2013) · Blood · doi:10.1182/blood-2013-02-484741 · Cited by 21
Miura, K., Hughes, M. C. B., Ungerer, J. P. J., Smith, D. D., & Green, A. C. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1358-y · Cited by 21
Ω-3 index as a prognosis tool in cardiovascular disease
Fielding, B. A. (2017) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000404 · Cited by 18
Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis
Quispe, R., Alfaddagh, A., Kazzi, B., Zghyer, F., Marvel, F. A., Blumenthal, R. S., Sharma, G., & Martin, S. S. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01031-9 · Cited by 17 · cited 1×
“The possible explanation for this heterogeneity includes differences in dosages between groups, the differences between study follow-ups, sample sizes, and lower event rates [39].”
BackgroundDietary Omega-3 Fatty Acid Intake and Mortality in CKD Population: A 1999–2014 NHANES Analysis
Li, W.-L., Zhang, N.-H., Ge, S.-W., & Xu, G. (2021) · American Journal of Nephrology · doi:10.1159/000520027 · Cited by 16
Kuma, H., Nagashima, R., Hatae, H., Tsuda, T., & Hamasaki, N. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.09.014 · Cited by 12
Cited by
The Ketogenic Diet and Cardiovascular Diseases
Dyńka, D., Kowalcze, K., Charuta, A., & Paziewska, A. (2023) · Nutrients · doi:10.3390/nu15153368 · Cited by 134
Khaksar, G., Kasemcholathan, S., & Sirikantaramas, S. (2024) · Horticulturae · doi:10.3390/horticulturae10040342 · Cited by 75
“These associations have been highlighted in studies by Breslow [38] and Rodriguez et al. [39].”
BackgroundFish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis
Lok, C. E., Farkouh, M., Hemmelgarn, B. R., Moist, L. M., Polkinghorne, K. R., Tomlinson, G., Tam, P., Tonelli, M., & Udell, J. A. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2513032 · Cited by 60
Larrosa, M., Gil‐Izquierdo, Á., González‐Rodríguez, L. G., Alférez, M. J. M., Juan, A. F. S., Sánchez-Gómez, Á., Calvo‐Ayuso, N., Ramos-Álvarez, J. J., Fernández‐Lázaro, D., López-Grueso, R., et al. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae082 · Cited by 67
Yang, Y., Xia, Y., Zhang, B., Li, D., Yan, J., Yang, J., Sun, J. P., Cao, H., Wang, Y., & Zhang, F. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1166702 · Cited by 49
Metadata
- Authors
- Rodriguez, D., Lavie, C. J., Elagizi, A., & Milani, R. V.
- Affiliations
- John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, Ochsner Clinical School—The University of Queensland School of Medicine, New Orleans, LA 70121, USA
- Ochsner Health System (US)
- Corresponding author
- Lavie, Carl J.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2022-12-03
- Volume
- 14
- Issue
- 23
- Pages
- 5146
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC9739673
- OpenAlex
- W4310682235
- Cited by
- 81
- References
- 94
- Citations by year
- 2026: 10 · 2025: 22 · 2024: 23 · 2023: 26
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Keywords
- omega-3 polyunsaturated fatty acids, fish oil, cardiovascular disease, hypertriglyceridemia, atherosclerotic cardiovascular disease, triglycerides, myocardial infarction, statin therapy, hyperlipidemia, cardiovascular mortality, autoimmune disease, chronic kidney disease, central nervous system disorders, COVID-19 pandemic
- MeSH terms
- COVID-19, Cardiovascular Diseases, Cholesterol, Humans, Hyperlipidemias, Cholesterol, HDL, Myocardial Infarction, Triglycerides, United States, Hypertriglyceridemia, Fatty Acids, Omega-3, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.